Calithera Biosciences

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Calithera Biosciences sits in the top decile of US sponsors by registered trial count (#696 of 15,742 sponsors by registered trial count).

22 total trials none currently recruiting 14 completed early-phase tilt top decile by trial count

Calithera Biosciences: 22 sponsored US clinical trials, none currently recruiting.

Calithera Biosciences sponsors 22 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 14 completed. 0 of these trials are in Phase 3-4 (later-stage) and 21 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Solid Tumor and Lymphoma Malignancies, with 1 trials.

Top-decile sponsor footprint

Calithera Biosciences ranks in the top decile of sponsors by registered trial count (#696 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 0/100

14 of 22 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (63.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

22 total, page 1 of 1

TERMINATED Phase 2

Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

NCT05319028
TERMINATED

NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial

NCT04698681
TERMINATED Phase 2

KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC

NCT04265534
COMPLETED Phase 1

Study to Evaluate the Safety of CB-280 in Patients With Cystic Fibrosis

NCT04279769
COMPLETED Phase 1

A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors

NCT03965845
TERMINATED Phase 1

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

NCT03875313
COMPLETED Phase 2

CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma

NCT03428217
COMPLETED Phase 1

A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma

NCT03357627
TERMINATED Phase 2

TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

NCT03123393
COMPLETED Phase 2

CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)

NCT03163667
COMPLETED Phase 2

Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC)

NCT03057600
COMPLETED Phase 1

A Comparative, Pharmacokinetic Study of CB-839 Capsule and Tablet Formulations in Healthy Adults

NCT02944435
TERMINATED Phase 1

A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors

NCT02834247
TERMINATED Phase 1

Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)

NCT02771626
COMPLETED Phase 2

Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy

NCT02756364
TERMINATED Phase 1

Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)

NCT02323113
COMPLETED Phase 1

Effect of Sapanisertib (MLN0128) on the QTc Interval in Participants With Advanced Solid Tumors

NCT02197572
COMPLETED Phase 1

Study of the Glutaminase Inhibitor CB-839 in Leukemia

NCT02071927
COMPLETED Phase 2

Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer

NCT02049957
COMPLETED Phase 1

Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors

NCT02071888
COMPLETED Phase 1

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

NCT02071862
COMPLETED Phase 1

A Study of TAK-659 in Adult Participants With Advanced Solid Tumor and Lymphoma Malignancies

NCT02000934

Phase Distribution

PhaseTrial count
Phase 1 13
Phase 2 8

Therapeutic Areas

Advanced Solid Tumor and Lymphoma Malignancies 1
Clear Cell Renal Cell Carcinoma 1
Advanced Solid Tumors 1

How the Calithera Biosciences early-phase archive is shaped

22 indexed studies, none listed as recruiting (0% open); 14 completed (64%).

Phase mix: 0 late (III/IV) vs 21 early (I/II) (early-phase heavy).

Top condition: Advanced Solid Tumor and Lymphoma Malignancies (1 trial), 2 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Calithera Biosciences: archived-pipeline peers nationwide

Peers matched on 22 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Calithera Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0510152025 0%5%10%15% Total trials Recruiting share Calithera BiosciencesAlaunos TherapeuticsAlexza PharmaceuticalsFate TherapeuticsGriffin Hospital10xBio22nd Century Group23andMe3-C Institute for Social Development
Calithera Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Calithera Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 22 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Calithera Biosciences page

22 registered trials is a research-attention snapshot, not an endorsement of Calithera Biosciences or any single study.

  • None of Calithera Biosciences's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Advanced Solid Tumor and Lymphoma Malignancies is the condition Calithera Biosciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced Solid Tumor and Lymphoma Malignancies trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Calithera Biosciences pipeline card: 22 registered trials from official public datasets.Report a data error.